Update
Share prices of KalVista (KALV) have recently fallen in light of some weakness amongst the biotechnology sector. The article below will assess KalVista's upcoming prospects in light of its cheaper prices.
Most recent 10-Q
Original conviction article
KalVista's share price surpassed the $30 PT within a few months of the article's creation, reaching as high as $34/share before stabilizing and receding:
Beginning in April, KalVista's momentum most likely fell victim to general biotech weakness, as evidenced by XBI's chart:
In looking for a technical entry, I often look at weekly or